Latest from BioRegenx
December 29, 2022
Findit, Inc. and BioRegenx, Inc. Announce they have Entered into a Definitive Agreement to Merge
Findit, Inc., a Nevada Corporation (OTC PINK:FDIT), owner of Findit.com, a full-service social networking platform that provides tools for members to increase brand awareness through content creation and sharing, resulting in indexing in search engines, announce they have entered into a Definitive Agreement with BioRegenx, Inc. ("BioRegenx") The merger has been approved by each company's board of directors and is anticipated to close in the first quarter of 2023, subject to customary closing conditions including regulatory approvals. The merger will constitute a major change of control of the public entity to the executive team of BioRegenx. The name of the public entity will be changed to BioRegenx, Inc. and the newly merged company will apply for a new ticker symbol that relates to the new name.
July 19, 2022
BioRegenx Announces Investor Update
CEO, William Resides announces that as of July 1st, 2022, BioRegenx has moved from due diligence to a binding letter of intent to merge with a public company. These steps also include drafting the definitive agreement for the final merger.
Latest from Subsidiaries
February 6, 2023
BioRegenx Announces Glycocalyx Biomarkers in Children Study Using Its Medical Testing Device GlycoCheck
BioRegenx, Inc. and its subsidiary Microvascular Health Solutions, LLC (MVHS), based in Alpine, Utah, announces a new peer-reviewed study published in Pediatric Critical Care Medicine on glycocalyx biomarkers in children with sepsis. In this study entitled “Endothelial and Glycocalyx Biomarkers in Children With Sepsis After One Bolus of Unbalanced or Balanced Crystalloids,” Jaime Fernández-Sarmiento and colleagues from Department of Pediatrics and Intensive Care, Fundación Cardioinfantil-Instituto de Cardiología, Universidad de La Sabana, Bogotá, Colombia, used the GlycoCheck™ system to test for the effect of different resuscitation fluids on the endothelial glycocalyx in children with sepsis and septic shock.
October 5, 2022
BioRegenx Announces Microvascular Differences Study in Individuals with Obesity at Risk of Developing Cardiovascular Disease
BioRegenx, Inc. and its subsidiary Microvascular Health Solutions, LLC (MVHS) based in Alpine, Utah, announces a new peer-reviewed study that reveals how individuals with obesity are at risk of developing cardiovascular disease. The study included the use of GlycoCheck™, a FDA registered Class 1 medical testing device. The paper is titled Microvascular Differences in Individuals With Obesity At Risk of Developing Cardiovascular Disease. The senior author is Dr. Hans Vink, the inventor of GlycoCheck™ and Chief Science Officer of BioRegenx. The objective was to investigate microvascular differences in individuals with obesity at risk for developing cardiovascular disease.
September 28, 2022
BioRegenx Announces Endothelial Glycocalyx Veterinary Study of Dogs and Cats Using the Testing Device GlycoCheck
Microvascular Health Solutions, LLC (MVHS), a BioRegenx subsidiary based in Alpine, Utah, announces that a new peer-reviewed study has been published using GlycoCheck, a medical testing device, exclusively distributed worldwide by MVHS. The study, titled The microvascular endothelial glycocalyx: An additional piece of the puzzle in veterinary medicine, looked at the role of the endothelial glycocalyx in dogs and cats. The study was published by the The Veterinary Journal, and it was authored by researchers at the Bristol Veterinary School, University of Bristol, Bristol, UK.
September 21, 2022
BioRegenx Announces Endothelial Glycocalyx Damage from COVID-19 Impacting Children Using the Medical Testing Device GlycoCheck
BioRegenx, Inc. and its subsidiary Microvascular Health Solutions, LLC (MVHS) based in Alpine, Utah, announces a new peer-reviewed study analyzing the impact of COVID-19 on children. The study included the use of GlycoCheck™, a FDA registered Class 1 medical testing device. The study of COVID-19 on children confirms how endothelial glycocalyx damage has been associated with severe inflammation, thrombotic phenomena, and profound hypoxemia in critically ill patients. The study, titled Case Report: Endothelial Glycocalyx Damage in Critically ill Patients With SARS-CoV-2-Related Multisystem Inflammatory Syndrome (MIS-C) reports that endothelial activation leads to a loss of the endothelium's antithrombotic properties which, under normal conditions, are maintained by the endothelial glycocalyx, the carbohydrate-rich layer that covers the luminal surface of endothelial cells. In children, one of the serious forms of SARS-CoV-2 virus disease (COVID-19) is multisystem inflammatory syndrome (MIS-C). This new disease is characterized by a large inflammatory response and frequent cardiovascular, cutaneous, and gastrointestinal disorders.